S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:CDMOAvid Bioservices Stock Price, Forecast & News

$8.49
+0.18 (+2.17 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.26
Now: $8.49
$8.77
50-Day Range
$5.93
MA: $7.09
$8.06
52-Week Range
$3.02
Now: $8.49
$8.77
Volume579,461 shs
Average Volume405,565 shs
Market Capitalization$479.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and Current Good Manufacturing Practices (CGMP) commercial manufacturing services focused on biopharmaceutical products derived from mammalian cell culture for biotechnology and pharmaceutical companies. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory submission and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Read More
Avid Bioservices logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.70 million
Book Value$0.74 per share

Profitability

Net Income$-10,470,000.00

Miscellaneous

Employees211
Market Cap$479.78 million
Next Earnings Date9/3/2020 (Estimated)
OptionableOptionable
$8.49
+0.18 (+2.17 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

How has Avid Bioservices' stock been impacted by Coronavirus (COVID-19)?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDMO stock has increased by 88.2% and is now trading at $8.49.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Avid Bioservices?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avid Bioservices
.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020.
View our earnings forecast for Avid Bioservices
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) announced its quarterly earnings results on Tuesday, June, 30th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.05. The biopharmaceutical company had revenue of $12.55 million for the quarter, compared to the consensus estimate of $9.55 million. Avid Bioservices had a negative return on equity of 22.29% and a negative net margin of 17.53%.
View Avid Bioservices' earnings history
.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2021 After-Hours earnings guidance on Tuesday, June, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $76-81 million, compared to the consensus revenue estimate of $83.85 million.

What price target have analysts set for CDMO?

4 brokers have issued 1 year price objectives for Avid Bioservices' shares. Their forecasts range from $7.50 to $11.00. On average, they expect Avid Bioservices' stock price to reach $9.38 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price.
View analysts' price targets for Avid Bioservices
.

Has Avid Bioservices been receiving favorable news coverage?

Press coverage about CDMO stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avid Bioservices earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Avid Bioservices
.

Are investors shorting Avid Bioservices?

Avid Bioservices saw a increase in short interest in January. As of January 15th, there was short interest totaling 2,630,000 shares, an increase of 14.8% from the December 31st total of 2,290,000 shares. Based on an average daily trading volume, of 370,100 shares, the days-to-cover ratio is presently 7.1 days.
View Avid Bioservices' Short Interest
.

Who are some of Avid Bioservices' key competitors?

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Biopharma (ARRY), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Dynavax Technologies (DVAX), Micron Technology (MU), Novavax (NVAX), QUALCOMM (QCOM), NVIDIA (NVDA) and Pfizer (PFE).

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:
  • Mr. Richard B. Hancock, Interim Pres, CEO & Director (Age 61, Pay $80.08k)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 47, Pay $477.95k)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $485.05k)
  • Mr. Richard Richieri, Chief Operations Officer (Age 55)
  • Ms. Lorna Larson, Sr. Director of HR

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Iszo Capital Management LP (6.28%), AltraVue Capital LLC (3.42%), Sargent Investment Group LLC (1.88%), Silvercrest Asset Management Group LLC (1.58%), Portolan Capital Management LLC (0.77%) and Schwartz Investment Counsel Inc. (0.58%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Joel Mccomb, Joseph Carleone, Mark R Bamforth, Mark R Ziebell, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices
.

Which major investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Iszo Capital Management LP, Essex Investment Management Co. LLC, Sargent Investment Group LLC, Schwartz Investment Counsel Inc., ClariVest Asset Management LLC, AltraVue Capital LLC, UBS Group AG, and State of Wisconsin Investment Board. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, and Mark R Ziebell.
View insider buying and selling activity for Avid Bioservices
.

Which major investors are buying Avid Bioservices stock?

CDMO stock was bought by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, Silvercrest Asset Management Group LLC, Marshall Wace LLP, Bank of New York Mellon Corp, McGuire Investment Group LLC, Goldman Sachs Group Inc., State Board of Administration of Florida Retirement System, and Signature Estate & Investment Advisors LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices
.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $8.49.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $479.78 million and generates $59.70 million in revenue each year. The biopharmaceutical company earns $-10,470,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Avid Bioservices employs 211 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.